Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

Following US President-elect Donald Trump's announcement that Robert F Kennedy (RFK) Jr will be appointed as head of the ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

An early lung cancer detection project co-led by the University of Colorado Cancer Center is expanding to two new states.

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Jefferies analyst Akash Tewari maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated ...